Skip to main content
SpringerLink
Log in

5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response

  • Original Paper
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

The purpose of the present study was to explore 5HT1A-mediated cortisol release in major depressive disorder (MDD) patients in order to determine whether the degree of 5HT1A-receptor sensitivity can predict response to treatment with selective serotonin reuptake inhibitors (SSRIs). We examined whether the sensitivity of the 5HT1A receptor, as measured by the difference in salivary cortisol levels immediately before and 90 min following the administration of a single dose of the 5HT1A-selective agonist buspirone, predicted treatment outcome following an 8-week, fixed-dose, open trial of the SSRI escitalopram in 17 outpatients with MDD. Change in cortisol levels before and 90 min after the administration of buspirone were not found to predict treatment outcome, whether defined as clinical response (50% or greater reduction in symptom severity), or remission of symptoms. In conclusion, in the present study, we did not find that the change in salivary cortisol levels following the administration of a 5HT1A-selective agonist predicted treatment outcome following an 8-week, fixed-dose, open-label trial of the SSRI escitalopram among outpatients with MDD. Although the 5HT1A-desensetization hypothesis is still a valid one, the results of the present study could not provide any evidence in support.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Amsterdam JD, Winokur A, Bryant S, Larkin J, Rickels K (1983) The dexamethasone suppression test as a predictor of treatment response. Psychopharmacology (Berl) 80:43–45

    Article  CAS  Google Scholar 

  2. Atkinson JH Jr, Kremer EF, Risch SC, Dana R, Janowsky DS (1986) Neuroendocrine responses in psychiatric and pain patients with major depression. Biol Psychiatry 21(7):612–620

    Article  PubMed  Google Scholar 

  3. Baghai TC, Schüle C, Zwanzger P, Minov C, Holme C, Padberg F, Bidlingmaier M, Strasburger CJ, Rupprecht R (2002) Evaluation of a salivary based combined dexamethasone/CRH test in patients with major depression. Psychoneuroendocrinology 27(3):385–399

    Article  CAS  PubMed  Google Scholar 

  4. Banki CM, Bissette G, Arato M, O’Connor L, Nemeroff CB (1987) CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 144:873–877

    CAS  PubMed  Google Scholar 

  5. Baumgartner A, Graf KJ, Kurten I (1986) Serial dexamethasone suppression tests in psychiatric illness: PartII. A study in major depressive disorder. Psychiatry Res 18(1):25–43

    Article  CAS  PubMed  Google Scholar 

  6. Berlin I, Warot D, Legout V, Guillemant S, Schollnhammer G, Puech A (1998) Blunted 5-HT-1A receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther 63(4):428–436

    Article  CAS  PubMed  Google Scholar 

  7. Blier P (2001) Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 62:12–17

    CAS  PubMed  Google Scholar 

  8. Catalan R, Gallard JM, Castellanos JM, Galard R (1998) Plasma corticotropin-releasing factor in depressive disorders. Biol Psychiatry 44:15–20

    Article  CAS  PubMed  Google Scholar 

  9. Cowen PJ (2000) Psychopharmacology of 5-HT(1A) receptors. Nucl Med Biol 27(5):437–439

    Article  CAS  PubMed  Google Scholar 

  10. Cryan JF, Leonard BE (2000) 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum Psychopharmacol 15(2):113–135

    Article  CAS  PubMed  Google Scholar 

  11. Dahl RE, Ryan ND, Puig-Antich J, Nguyen NA, al-Shabbout M, Meyer VA, Perel J (1991) 24-hour cortisol measures in adolescents with major depression: a controlled study. Biol Psychiatry 30(1):25–36

    Article  CAS  PubMed  Google Scholar 

  12. Dinan TG (1996) Serotonin and the regulation of hypothalamic–pituitary–adrenal axis function. Life Sci 58(20):1683–1694

    Article  CAS  PubMed  Google Scholar 

  13. Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, Mathis C (2007) Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 34(7):865–877

    Article  CAS  PubMed  Google Scholar 

  14. Evans DL, Nemeroff CB, Haggerty JJ Jr, Pedersen CA (1987) Use of the dexamethazone suppression test with DSM-III criteria in psychiatrically hospitalized adolescents. Psychoneuroendocrinology 12(3):203–209

    Article  CAS  PubMed  Google Scholar 

  15. First BM, Spitzer RL, Gibbon M, Williams JBW (1995) Structured clinical interview for DSM-IV axis I disorders—patient edition (SCID I/P). Biometrics Research Department, State Psychiatric Institute, New York

  16. Galard R, Gallart JM, Catalan R, Schwartz S, Arguello JM, Castellanos JM (1991) Salivary cortisol levels and their correlation with plasma ACTH levels in depressed patients before and after the DST. Am J Psychiatry 148(4):505–508

    CAS  PubMed  Google Scholar 

  17. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62

    Article  CAS  PubMed  Google Scholar 

  18. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, Künzel HE, Pfennig A, Uhr M, Holsboer F (2007) Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression—a potential biomarker? Biol Psychiatry 62(1):47–54

    Article  CAS  PubMed  Google Scholar 

  19. Ising M, Künzel HE, Binder EB, Nickel T, Modell S, Holsboer F (2005) The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 29(6):1085–1093

    Article  CAS  PubMed  Google Scholar 

  20. Janicak PG, Pandey GN, Sharma R, Boshes R, Bresnahan D, Davis JM (1987) Pretreatment dexamethasone suppression test as a predictor of response to phenelzine. J Clin Psychiatry 48(12):480–482

    CAS  PubMed  Google Scholar 

  21. Kin NM, Nair NP, Schwartz G, Ahmed SK, Holm P, Katona C, Kragh-Sorensen P, Klitgaard N, Song WY, West TE, Stage K (1997) The dexamethazone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline. Biol Psychiatry 42(10):925–931

    Article  CAS  PubMed  Google Scholar 

  22. Leonard BE (2005) The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry 20(3):S302–S306

    Article  PubMed  Google Scholar 

  23. Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME (1999) 5-HT1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 20(6):628–639

    Article  CAS  PubMed  Google Scholar 

  24. Linkowski P, Mandlewicz J, Kerkhofs M, Leclercq R, Goldstein J, Brasseur M, Copinschi G, Van Cauter E (1987) 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J Clin Endocrinol Metab 65(1):141–152

    Article  CAS  PubMed  Google Scholar 

  25. Michael A, Jenaway A, Paykel ES, Herbert J (2000) Altered salivary dehydroepiandrosterone levels in major depression. Biol Psychiatry 48(10):989–995

    Article  CAS  PubMed  Google Scholar 

  26. Moffoot AP, O’Carroll RE, Bennie J, Carroll S, Dick H, Ebmeier KP, Goodwin GM (1994) Diurnal variation of mood and neuropsychological function in major depression with melancholia. J Affect Disord 32(4):257–269

    Article  CAS  PubMed  Google Scholar 

  27. Navinés R, Martín-Santos R, Gómez-Gil E, Martínez de Osaba MJ, Imaz ML, Gastó C (2007) Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response. Psychoneuroendocrinology 32(4):411–416

    Article  PubMed  Google Scholar 

  28. O’Toole SM, Sekula LK, Rubin RT (1997) Pituitary–adrenal cortical axis measures as predictors of sustained remission in major depression. Biol Psychiatry 42(2):85–89

    Article  PubMed  Google Scholar 

  29. Plotsky PM, Owens MH, Nemeroff CB (1998) Psychoneuroendocrinology of depression Hypothalamic–pituitary–adrenal axis. Psychiatr Clin North Am 21(2):293–307

    Article  CAS  PubMed  Google Scholar 

  30. Posener JA, deBattista C, Williams GH, Chmura Kraemer H, Kalezhan BM, Schatzberg AF (2000) 24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 57(8):755–760

    Article  CAS  PubMed  Google Scholar 

  31. Raadscheer FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF (1994) Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60:436–443

    Article  Google Scholar 

  32. Rausch JL, Stahl SM, Hauger RL (1990) Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients. Biol Psychiatry 28(1):73–78

    Article  CAS  PubMed  Google Scholar 

  33. Schüle C, Baghai TC, Eser D, Häfner S, Born C, Herrmann S, Rupprecht R (2009) The combined dexamethasone/CRH test (DEX/CRH test) and prediction of acute treatment response in major depression. PLoS ONE 4(1):e4324

    Article  PubMed  Google Scholar 

  34. Stahl SM (1992) Neuroendocrine markers of serotonin responsivity in depression. Prog Neuropsychopharmacol Biol Psychiatry 16(5):655–659

    Article  CAS  PubMed  Google Scholar 

  35. Stahl S (1994) 5HT1A receptors and pharmacotherapy: Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 30(1):39–43

    CAS  PubMed  Google Scholar 

  36. Stahl SM (1998) Mechanism of action of selective serotonin reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51(3):215–235

    Article  CAS  PubMed  Google Scholar 

  37. Thase ME, Dube S, Bowler K, Howland RH, Myers JE (1996) Hypothalamic–pituitary–adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients. Am J Psychiatry 153(7):886–891

    CAS  PubMed  Google Scholar 

  38. Weber B, Lewicka S, Deuschle M, Colla M, Vecsei P, Heuser I (2000) Increased diurnal plasma concentrations of cortisone in depressed patients. J Clin Endocrinol Metab 85(3):1133–1136

    Article  CAS  PubMed  Google Scholar 

  39. Wong ML, Kling MA, Munson PJ, Listwak S, Licino J, Prolo P, Karp B, McCutcheon IE, Geracioti TJ Jr, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP, Oldfield EH, McCann SM, Gold PW (2000) Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 97(1):325–330

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by the Harvard Medical School/Kaplen Fellowship and Livingston Award in Depression Research (GIP).

Author information

Authors and Affiliations

  1. Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, WACC#812, Boston, MA, 02114, USA

    George I. Papakostas & Maurizio Fava

  2. Depression Clinical and Research Program, Massachusetts General Hospital, 50 Staniford Street, Suite 401, Boston, MA, 02114, USA

    Sarah E. Chuzi & Jessica L. Sousa

Authors
  1. George I. Papakostas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah E. Chuzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jessica L. Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Fava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George I. Papakostas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papakostas, G.I., Chuzi, S.E., Sousa, J.L. et al. 5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response. Eur Arch Psychiatry Clin Neurosci 260, 175–180 (2010). https://doi.org/10.1007/s00406-009-0035-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-009-0035-z

Keywords

Search

Navigation